Search

Ebrahim Mahmoud,1 Sarah Al Mansour,1 Mohammad Bosaeed,1– 3 Ahmad Alharbi,1 Abdulrahman Alsaedy,1,2 Sameera Aljohani,2,4 Bassam Alalwan,4 Adel Alothman1,2, † 1Division of Infectious Diseases, Department of Medicine, King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia; 2College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; 3King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia; 4Department of Pathology & Laboratory Medicine, King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia†Doctor Adel Al Othman passed away on June 8, 2020Correspondence: Ebrahim MahmoudDivision of Infectious Diseases, Department of Medicine, King Abdulaziz Medical City - Riyadh, P.O. Box 22490, Riyadh 11426, Saudi ArabiaTel +966 500081418Email emahmoud85@gmail.comAbstract: While methicillin-resistant Staphylococcus aureus (MRSA) bacteremia has poor outcomes, we describe our experience with Ceftobiprole mainly as a combination therapy for the treatment of MRSA bacteremia. All the cases of MRSA bacteremia in our center at the King Abdulaziz Medical City (KAMC), Riyadh, that had undergone Ceftobiprole treatment were included. We had six cases of MRSA bacteremia between 2018 and 2019, secondary to different infectious syndromes including endocarditis. There was a severe infection that required intensive care unit (ICU) admission in four cases. Ceftobiprole is used in combination with vancomycin in four cases. On day 14, all cases had a favorable outcome with microbiological and clinical improvement. However, three patients died after months of suffering from bacteremia from unrelated causes for the infection. The clinical outcome in our series of treatment of MRSA bacteremia using Ceftobiprole was favorable. Further studies for the evaluation of the use of Ceftobiprole in MRSA bacteremia should be encouraged.Keywords: methicillin-resistant Staphylococcus aureus, bacteremia, Ceftobiprole, treatment